Lisa J Frigati1,2, Katalin A Wilkinson3,4, Stanzi le Roux5, Karryn Brown5, Sheena Ruzive3, Leah Githinji1, Wonita Petersen1, Sabine Belard6,7, Mark F Cotton2, Landon Myer5, Heather J Zar1,8. 1. Department of Paediatrics and Child Health, University of Cape Town, Cape, South Africa. 2. Family Center for Research with Ubuntu (FAMCRU), Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa. 3. Wellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 4. The Francis Crick Institute, London, United Kingdom. 5. Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. 6. Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany. 7. Berlin Institute of Health, Berlin, Germany. 8. SAMRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
Abstract
INTRODUCTION: There are limited data on Tuberculosis (TB) in adolescents with perinatally acquired HIV (APHIV). We examined the incidence and determinants of TB infection and disease in the Cape Town Adolescent Antiretroviral Cohort (CTAAC). METHODS: Youth between nine and fourteen years on antiretroviral therapy (ART) for more than six months in public sector care, and age-matched HIV-negative adolescents, were enrolled between July 2013 through March 2015 and followed six-monthly. Data were censored on 31 October 2018. Symptom screening, chest radiograph, viral load, CD4 count, QuantiFERON (QFT) and sputum for Xpert MTB/RIF, microscopy, culture and sensitivity were performed annually. TB infection was defined by a QFT of >0.35 IU/mL. TB diagnosis was defined as confirmed (culture or Xpert MTB/RIF positive) or unconfirmed (clinical diagnosis and started on TB treatment). Analyses examined the incidence and determinants of TB infection and disease. RESULTS: Overall 496 HIV+ and 103 HIV-negative participants (median age at enrolment 12 years (interquartile range, IQR 10.6 to 13.3) were followed for a median of 3.1 years (IQR 3.0 to 3.4); 50% (298/599) were male. APHIV initiated ART at median age 4.4 years (IQR 2.1 to 7.6). At enrolment, 376/496 (76%) had HIV viral load <40 copies/mL, median CD4 count was 713 cells/mm3 and 179/559 (32%) were QFT+, with no difference by HIV status (APHIV 154/468, 33%; HIV negative 25/91, 27%; p = 0.31). The cumulative QFT+ prevalence was similar (APHIV 225/492, 46%; 95%CI 41% to 50%; HIV negative 44/98, 45%; 95% CI 35% to 55%; p = 0.88). APHIV had a higher incidence of all TB disease than HIV-negative adolescents (2.2/100PY, 95% CI 1.6 to 3.1 vs. 0.3/100PY, 95% CI 0.04 to 2.2; IRR 7.36, 95% CI 1.01 to 53.55). The rate of bacteriologically confirmed TB in APHIV was 1.3/100 PY compared to 0.3/100PY for HIV-negative adolescents, suggesting a fourfold increased risk of developing TB disease in APHIV despite access to ART. In addition, a positive QFT at enrolment was not predictive of TB in this population. CONCLUSIONS: High incidence rates of TB disease occur in APHIV despite similar QFT conversion rates to HIV-negative adolescents. Strategies to prevent TB in this vulnerable group must be strengthened.
INTRODUCTION: There are limited data on Tuberculosis (TB) in adolescents with perinatally acquired HIV (APHIV). We examined the incidence and determinants of TB infection and disease in the Cape Town Adolescent Antiretroviral Cohort (CTAAC). METHODS: Youth between nine and fourteen years on antiretroviral therapy (ART) for more than six months in public sector care, and age-matched HIV-negative adolescents, were enrolled between July 2013 through March 2015 and followed six-monthly. Data were censored on 31 October 2018. Symptom screening, chest radiograph, viral load, CD4 count, QuantiFERON (QFT) and sputum for Xpert MTB/RIF, microscopy, culture and sensitivity were performed annually. TB infection was defined by a QFT of >0.35 IU/mL. TB diagnosis was defined as confirmed (culture or Xpert MTB/RIF positive) or unconfirmed (clinical diagnosis and started on TB treatment). Analyses examined the incidence and determinants of TB infection and disease. RESULTS: Overall 496 HIV+ and 103 HIV-negative participants (median age at enrolment 12 years (interquartile range, IQR 10.6 to 13.3) were followed for a median of 3.1 years (IQR 3.0 to 3.4); 50% (298/599) were male. APHIV initiated ART at median age 4.4 years (IQR 2.1 to 7.6). At enrolment, 376/496 (76%) had HIV viral load <40 copies/mL, median CD4 count was 713 cells/mm3 and 179/559 (32%) were QFT+, with no difference by HIV status (APHIV 154/468, 33%; HIV negative 25/91, 27%; p = 0.31). The cumulative QFT+ prevalence was similar (APHIV 225/492, 46%; 95%CI 41% to 50%; HIV negative 44/98, 45%; 95% CI 35% to 55%; p = 0.88). APHIV had a higher incidence of all TB disease than HIV-negative adolescents (2.2/100PY, 95% CI 1.6 to 3.1 vs. 0.3/100PY, 95% CI 0.04 to 2.2; IRR 7.36, 95% CI 1.01 to 53.55). The rate of bacteriologically confirmed TB in APHIV was 1.3/100 PY compared to 0.3/100PY for HIV-negative adolescents, suggesting a fourfold increased risk of developing TB disease in APHIV despite access to ART. In addition, a positive QFT at enrolment was not predictive of TB in this population. CONCLUSIONS: High incidence rates of TB disease occur in APHIV despite similar QFT conversion rates to HIV-negative adolescents. Strategies to prevent TB in this vulnerable group must be strengthened.
Authors: Stephen M Graham; Tahmeed Ahmed; Farhana Amanullah; Renee Browning; Vicky Cardenas; Martina Casenghi; Luis E Cuevas; Marianne Gale; Robert P Gie; Malgosia Grzemska; Ed Handelsman; Mark Hatherill; Anneke C Hesseling; Patrick Jean-Philippe; Beate Kampmann; Sushil Kumar Kabra; Christian Lienhardt; Jennifer Lighter-Fisher; Shabir Madhi; Mamodikoe Makhene; Ben J Marais; David F McNeeley; Heather Menzies; Charles Mitchell; Surbhi Modi; Lynne Mofenson; Philippa Musoke; Sharon Nachman; Clydette Powell; Mona Rigaud; Vanessa Rouzier; Jeffrey R Starke; Soumya Swaminathan; Claire Wingfield Journal: J Infect Dis Date: 2012-03-22 Impact factor: 5.226
Authors: H Mahomed; T Hawkridge; S Verver; L Geiter; M Hatherill; D-A Abrahams; R Ehrlich; W A Hanekom; G D Hussey Journal: Int J Tuberc Lung Dis Date: 2011-03 Impact factor: 2.373
Authors: B J Marais; R P Gie; H S Schaaf; A C Hesseling; C C Obihara; L J Nelson; D A Enarson; P R Donald; N Beyers Journal: Int J Tuberc Lung Dis Date: 2004-03 Impact factor: 2.373
Authors: Kathryn J Snow; Lisa J Nelson; Charalambos Sismanidis; Susan M Sawyer; Stephen M Graham Journal: Epidemiol Infect Date: 2018-04-15 Impact factor: 4.434
Authors: Videlis Nduba; Anna H Van't Hoog; Annefleur de Bruijn; Ellen M H Mitchell; Kayla Laserson; Martien Borgdorff Journal: BMC Infect Dis Date: 2019-08-02 Impact factor: 3.090
Authors: Alexander W Kay; Helena Rabie; Elizabeth Maleche-Obimbo; Moorine Penninah Sekadde; Mark F Cotton; Anna M Mandalakas Journal: Pathogens Date: 2021-12-29
Authors: Patricia Moscibrodzki; Leslie A Enane; Graeme Hoddinott; Meredith B Brooks; Virginia Byron; Jennifer Furin; James A Seddon; Lily Meyersohn; Silvia S Chiang Journal: Pathogens Date: 2021-12-08